Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/9/2025 | $440.00 | Hold → Sell | Deutsche Bank |
6/5/2025 | Hold → Buy | Erste Group | |
12/2/2024 | $522.00 → $650.00 | Equal-Weight → Overweight | Morgan Stanley |
8/2/2024 | $380.00 → $510.00 | Neutral → Buy | Redburn Atlantic |
7/10/2024 | $462.00 → $512.00 | Buy | Citigroup |
5/30/2024 | $500.00 | Buy | Goldman |
11/17/2023 | $318.00 | Buy | HSBC Securities |
7/19/2023 | $377.00 | Outperform | Robert W. Baird |
SUNNYVALE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- When Seattle resident Dan Larson was diagnosed with lung cancer in 2023, his only exposure to robotic technology was through his work as a quality engineer at Boeing. He could never have imagined that robotic technology made by Intuitive, the pioneer of robotic-assisted surgery, would one day play a pivotal role in his health care. Having experienced the loss of his father to lung cancer, Dan was determined to overcome his own diagnosis and enjoy his retirement with his family. Under the care of clinicians at MultiCare Tacoma General Hospital in Washington, Dan underwent two robotic lung biopsies with the Ion Endoluminal System, Intuit
President Dave Rosa promoted to CEOCurrent CEO Gary Guthart to become executive chair of Intuitive's boardCurrent Board Chair Craig Barratt to become lead independent director SUNNYVALE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of President Dave Rosa to chief executive officer, effective July 1, 2025. At that time, current CEO Gary Guthart will become the executive chair of Intuitive's board of directors, and current Board Chair Craig Barratt will become lead independent director. Guthart will work closely with Rosa to support a smooth t
SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical incisions for select procedures. This clearance extends the da Vinci SP's capabilities in colorectal surgery, building upon procedures previously cleared by the FDA in November 2024, which include transabdominal procedures - low anterior resection, total mesorec